(IN BRIEF) Researchers at the Technical University of Munich (TUM) have developed an inhalable RNA-based drug that targets macrophages, overactive immune cells often responsible for lung damage in diseases like Covid-19. The drug, RCS-21, inhibits the activity of microRNA 21, … Read the full press release →
Posted in Business, Education, Germany, Healthcare, Industrial, Management, News, Pharma & Biotech, Science
Tagged Christina Beck, Inhalable, macrophages, medicine, microRNA 21, pneumonia, RCS-21, RNA Drug, RNATICS, Severe Lung Inflammation, Stefan Engelhardt, Technical University of Munich, trimannose, wellness